Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Diabetes

Journal Scan / Research · October 04, 2023

Initiation of Treatment With SGLT2 Inhibitors and GLP-1 Receptor Agonists According to the Level of Frailty in People With Type 2 Diabetes and CVD in Denmark

The Lancet


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet
Initiation of SGLT2 inhibitors and GLP-1 receptor agonists according to level of frailty in people with type 2 diabetes and cardiovascular disease in Denmark: a cross-sectional, nationwide study
Lancet 2023 Sep 18;[EPub Ahead of Print], ME Malik, JH Butt, JE Strange, AC Falkentoft, J Jensen, C Andersson, D Zahir, E Fosbøl, MC Petrie, N Sattar, JJV McMurray, L Køber, M Schou

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading